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**Abstract**

Translational researches in schizophrenia have revealed the many aspects of biological evidence for schizophrenia. To find the intracellular signaling pathway responsible for antipsychotic medications, metabolic adverse events induced by atypical antipsychotics can provide a window to look for the novel molecular target mediating the therapeutic action of antipsychotics. Mammalian target of rapamycin (mTOR) is master switch regulating protein translation through sensing cellular energy state. Akt and mitogen activated protein kinase (MAPK) pathways cooperatively regulate mTOR signal pathway. In addition, AMP-activated protein kinase (AMPK), another major metabolic sensor maintaining metabolic homeostasis, interacts with mTOR to regulate the cellular response to various stimuli. Recent studies have suggested that mTOR signal pathway is involved in mood and psychotomimetic behavioral changes as well as epileptogenesis. In this talk, involvement of mTOR and AMPK signal pathways in the therapeutic and pathogenetic mechanisms of psychotic disorders will be reviewed and discussed based on the recent findings.
